Evidence map›Paper›PMID 30256491›Full record

Trial reportHuman brain mapping2019

White matter tract microstructure of the mPFC-amygdala predicts interindividual differences in placebo response related to treatment in migraine patients.

Jixin Liu, Junya Mu, Tao Chen, Ming Zhang, Jie Tian

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Human brain mapping, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jixin LiuCenter for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, Peoples Republic of China.ORCID 0000-0002-4239-1201
Junya MuCenter for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, Peoples Republic of China.
Tao ChenCenter for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, Peoples Republic of China.
Ming ZhangDepartment of Medical Imaging, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Peoples Republic of China.
Jie TianCenter for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, Peoples Republic of China.
Ministry of Education of the People's Republic of China · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

Fundamental Research Funds for the Central Universities JB171201National Natural Science Foundation of China 81471737National Natural Science Foundation of China 81473603National Natural Science Foundation of China 81501547National Natural Science Foundation of China 81571640Science and Technology Planning Program of Henan Province 162102210218Science and Technology Planning Program of Henan Province 172106000074
6 · The paper itself

Abstract

To investigate whether interindividual variability of white matter (WM) tract microstructure of the medial prefrontal cortex (mPFC)-amygdala circuit could predict 8-week placebo treatment outcomes in patients with migraine without aura (MO) using diffusion tensor imaging (DTI) with a tractography atlas-based analysis algorithm and a linear support vector machine algorithm. This study received institutional review board approval, and all subjects gave informed consent. One hundred and twenty-four MO had an 8-week sham acupuncture treatment. Patients were subdivided into recovering (MOr, >50% improvement in migraine attack frequency after treatment) and persisting (MOp, <50% reduction in number of migraine days). Neuroimaging was collected via magnetic resonance imaging (MRI) in all subjects. Patients were imaged during the interictal phase of migraine (at least 72 hr after, and not within 24 hr of a migraine) before the treatment. WM microstructures were quantified along the selected fiber pathway and were used to evaluate the discrimination performance for classifying MOr and MOp. The combined features of diffusion measures from vertices along the pathways of the mPFC-amygdala accurately discriminated MOr from MOp migraineurs with an accuracy of 84.0% (p < .005, permutation test). The most discriminative WM features that contributed to the classification were located in the external capsule and ACC/mPFC. Our findings suggested that the variability of placebo treatment outcomes in migraineurs could be predicted from priori diffusion measures along the fiber pathways of the mPFC-amygdala, which may demonstrate a potential of WM neuroimaging features as imaging markers for identifying placebo responders in migraine patients.

Indexed as

Outcome Assessment, Health CarePlacebo EffectAcupuncture TherapyAdultAmygdalaBiomarkersDiffusion Tensor ImagingHumansIndividualityMigraine without AuraPlacebosPrefrontal CortexWhite MatterYoung AdultBiomarkersPlacebosmigraineplacebopredictionwhite matter tract microstructure

Identifiers

PMID30256491
PMCPMC6865394
OpenAlexW2890227291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.